2024
American Radium Society Appropriate Use Criteria on Cardiac Toxicity Prevention and Management After Thoracic Radiotherapy
Amini A, Zaha V, Hamad E, Woodard P, Rimner A, Chang J, Chun S, Donington J, Edelman M, Gubens M, Higgins K, Iyengar P, Juloori A, Movsas B, Ning M, Park H, Rodrigues G, Wolf A, Simone C. American Radium Society Appropriate Use Criteria on Cardiac Toxicity Prevention and Management After Thoracic Radiotherapy. Journal Of Thoracic Oncology 2024, 19: 1654-1667. PMID: 39313150, PMCID: PMC11665043, DOI: 10.1016/j.jtho.2024.09.1433.Peer-Reviewed Original ResearchConceptsCardiac toxicityCardiac comorbiditiesThoracic radiotherapyToxicity preventionAmerican Radium Society Appropriate Use CriteriaAbsence of cardiovascular risk factorsLow riskHigh riskMultidisciplinary consensus guidelinesTreatment-related risksAppropriate use criteriaCardiovascular risk factorsVariants of patientsThoracic malignanciesModified Delphi methodologyCardiac substructuresConsensus guidelinesRadiotherapyRisk factorsCardiac imagingComorbiditiesDose exposurePatientsSystematic reviewThoracicAmerican Radium Society Appropriate Use Criteria for Unresectable Locally Advanced Non–Small Cell Lung Cancer
Rodrigues G, Higgins K, Rimner A, Amini A, Chang J, Chun S, Donington J, Edelman M, Gubens M, Iyengar P, Movsas B, Ning M, Park H, Wolf A, Simone C. American Radium Society Appropriate Use Criteria for Unresectable Locally Advanced Non–Small Cell Lung Cancer. JAMA Oncology 2024, 10: 799-806. PMID: 38602670, PMCID: PMC11665040, DOI: 10.1001/jamaoncol.2024.0294.Peer-Reviewed Original ResearchConceptsLocally advanced non-small cell lung cancerAmerican Radium Society Appropriate Use CriteriaAdvanced non-small cell lung cancerAmerican Radium SocietyAppropriate use criteriaNon-small cell lung cancerLA-NSCLCUnresectable LA-NSCLCCell lung cancerTreatment of locally advanced non-small cell lung cancerUnresectable locally advanced non-small cell lung cancerLung cancerIntensity-modulated radiotherapy techniqueDecades of clinical trialsPlatinum-based chemoradiationLung cancer radiotherapyEvidence-based consensus documentMultidisciplinary patient careEvidence-based guidelinesRadiotherapy techniquesSalvage therapyFractionation schedulesLocal recurrenceSystemic therapyCancer radiotherapyExecutive summary of the American Radium Society appropriate use criteria for brain metastases in epidermal growth factor receptor mutated-mutated and ALK-fusion non-small cell lung cancer
Nagpal S, Milano M, Chiang V, Soltys S, Brackett A, Halasz L, Garg A, Sahgal A, Ahluwalia M, Tom M, Palmer J, Knisely J, Chao S, Gephart M, Wang T, Lo S, Chang E. Executive summary of the American Radium Society appropriate use criteria for brain metastases in epidermal growth factor receptor mutated-mutated and ALK-fusion non-small cell lung cancer. Neuro-Oncology 2024, 26: 1195-1212. PMID: 38459978, PMCID: PMC11226873, DOI: 10.1093/neuonc/noae041.Peer-Reviewed Original ResearchNon-small cell lung cancerTyrosine kinase inhibitorsCell lung cancerCentral nervous systemAmerican Radium SocietyALK-fusionBrain metastasesAmerican Radium Society Appropriate Use CriteriaLung cancerSequence of tyrosine kinase inhibitorsALK tyrosine kinase inhibitorsTreatment of brain metastasesEGFR tyrosine kinase inhibitorsWhole-brain RTEpidermal growth factor receptorGrowth factor receptorAppropriate use criteriaBrain RTEGFR-mutantRadiotherapyTreatment optionsFactor receptorKinase inhibitorsNervous systemLiterature search
2023
American Radium Society Appropriate Use Criteria for Radiation Therapy in the Multidisciplinary Management of Thymic Carcinoma
Chun S, Rimner A, Amini A, Chang J, Donington J, Edelman M, Geng Y, Gubens M, Higgins K, Iyengar P, Movsas B, Ning M, Park H, Rodrigues G, Wolf A, Simone C. American Radium Society Appropriate Use Criteria for Radiation Therapy in the Multidisciplinary Management of Thymic Carcinoma. JAMA Oncology 2023, 9: 971-980. PMID: 37186595, PMCID: PMC11665036, DOI: 10.1001/jamaoncol.2023.1175.Peer-Reviewed Original ResearchConceptsAmerican Radium SocietyMultidisciplinary consensus guidelinesThymic carcinomaConsensus guidelinesRadiation therapyOncological managementAmerican Radium Society Appropriate Use CriteriaManagement of thymic carcinomaIntensity-modulated radiation therapyConventionally fractionated radiationElective nodal irradiationEnglish-language medical literatureMinimally invasive thymectomyReduce radiation exposureAppropriate use criteriaNodal irradiationModified Delphi methodologyMultidisciplinary managementProton therapyInfiltrative natureCarcinomaConsensus recommendationsProspective dataStage IRadiation exposure
2022
Executive summary of American Radium Society’s appropriate use criteria for the postoperative management of lower grade gliomas
Tom MC, Milano MT, Chao ST, Soltys SG, Knisely JPS, Sahgal A, Nagpal S, Lo SS, Jabbari S, Wang TJC, Ahluwalia MS, Simonson M, Palmer JD, Gephart MH, Halasz LM, Garg AK, Chiang VLS, Chang EL. Executive summary of American Radium Society’s appropriate use criteria for the postoperative management of lower grade gliomas. Radiotherapy And Oncology 2022, 170: 79-88. PMID: 35367527, DOI: 10.1016/j.radonc.2022.03.018.Peer-Reviewed Original ResearchConceptsLow-grade gliomasAppropriate use criteriaGrade 2 gliomasGrade 3 gliomasPostoperative managementGrade gliomasIDH-mutant oligodendrogliomasPostoperative therapyRadiotherapy doseAmerican Radium Society Appropriate Use CriteriaGrade 2Gross total surgical resectionImmediate adjuvant therapyHigh-risk featuresType of chemotherapyLow-risk featuresAppropriate treatment optionsIDH-mutant astrocytomasAdjuvant therapyModality therapySurgical resectionConsensus guidelinesTreatment optionsClose surveillanceConsensus recommendations
2021
Primary Mediastinal B Cell Lymphoma in the Positron-Emission Tomography Era Executive Summary of the American Radium Society Appropriate Use Criteria
Hoppe BS, Advani R, Milgrom SA, Bakst RL, Ballas LK, Dabaja BS, Flowers CR, Ha CS, Mansur DB, Metzger ML, Pinnix CC, Plastaras JP, Roberts KB, Smith SM, Terezakis SA, Kirwan JM, Constine LS. Primary Mediastinal B Cell Lymphoma in the Positron-Emission Tomography Era Executive Summary of the American Radium Society Appropriate Use Criteria. International Journal Of Radiation Oncology • Biology • Physics 2021, 111: 36-44. PMID: 33774076, DOI: 10.1016/j.ijrobp.2021.03.035.Peer-Reviewed Original ResearchConceptsPrimary mediastinal B-cell lymphomaMediastinal B-cell lymphomaB-cell lymphomaPET/CT responsePositron emission tomographyCell lymphomaDeauville scaleRadiation therapyCT responseAmerican Radium Society Appropriate Use CriteriaLong-term treatment-related morbiditySystematic reviewTreatment-related morbidityConsolidative radiation therapyAppropriate use criteriaEvidence-based guidelinesNon-Hodgkin lymphomaMeta-Analyses (PRISMA) guidelinesPreferred Reporting ItemsChemoimmunotherapy strategiesCurable subtypeAdditional therapyChemoimmunotherapy regimensRefractory diseasePediatric oncologists
2020
Nodular lymphocyte predominant Hodgkin lymphoma: executive summary of the American radium society appropriate use criteria
Ballas LK, Metzger ML, Milgrom SA, Advani R, Bakst RL, Dabaja BS, Flowers CR, Ha CS, Hoppe BS, Mansur DB, Pinnix CC, Plastaras JP, Roberts KB, Smith SM, Terezakis SA, Constine LS. Nodular lymphocyte predominant Hodgkin lymphoma: executive summary of the American radium society appropriate use criteria. Leukemia & Lymphoma 2020, 62: 1057-1065. PMID: 33274673, DOI: 10.1080/10428194.2020.1852559.Peer-Reviewed Original ResearchConceptsNodular lymphocyte predominant Hodgkin lymphomaHodgkin's lymphomaAmerican Radium Society Appropriate Use CriteriaLymphocyte predominant Hodgkin lymphomaAppropriate use criteriaMultidisciplinary expert panelPredominant Hodgkin lymphomaClassical Hodgkin lymphomaRare lymphomaClinical variantsAmerican Radium SocietyConsensus recommendationsGuideline developmentRadiation oncologistsLymphomaStrong recommendationsCompelling dataConsensus methodologyUse criteriaExpert panelExpert opinionExecutive summaryLiterature reviewGuidelinesPatientsExecutive summary from American Radium Society’s appropriate use criteria on neurocognition after stereotactic radiosurgery for multiple brain metastases
Milano MT, Chiang VLS, Soltys SG, Wang TJC, Lo SS, Brackett A, Nagpal S, Chao S, Garg AK, Jabbari S, Halasz LM, Gephart MH, Knisely JPS, Sahgal A, Chang EL. Executive summary from American Radium Society’s appropriate use criteria on neurocognition after stereotactic radiosurgery for multiple brain metastases. Neuro-Oncology 2020, 22: 1728-1741. PMID: 32780818, PMCID: PMC7746939, DOI: 10.1093/neuonc/noaa192.Peer-Reviewed Original ResearchConceptsWhole brain radiotherapyAsymptomatic brain metastasesGood performance statusBrain metastasesMultiple brain metastasesAppropriate use criteriaStereotactic radiosurgeryPerformance statusTreatment optionsAmerican Radium Society Appropriate Use CriteriaHippocampal Sparing-Whole Brain RadiotherapySystematic reviewConventional whole brain radiotherapySingle-fraction stereotactic radiosurgeryProgressive extracranial diseasePoor performance statusAppropriate treatment optionsQuality of evidenceBrainstem metastasesExtracranial diseaseConsensus guidelinesOptimal treatmentSystemic optionsNeurocognitive outcomesPatients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply